Enoxaparin sodium and Cavernous sinus thrombosis - a phase IV clinical study of FDA data

Summary:

Cavernous sinus thrombosis is reported as a side effect among people who take Enoxaparin sodium (enoxaparin sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Furosemide, and have Headache.

The phase IV clinical study analyzes which people have Cavernous sinus thrombosis when taking Enoxaparin sodium. It is created by eHealthMe based on reports of 24,091 people who have side effects when taking Enoxaparin sodium from the FDA, and is updated regularly.

What is Enoxaparin sodium?

Enoxaparin sodium has active ingredients of enoxaparin sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 24,181 Enoxaparin sodium users. Check the latest studies of Enoxaparin sodium.

What is Cavernous sinus thrombosis?

Cavernous sinus thrombosis (formation of a blood clot in brain) is found to be associated with 58 drugs and 144 conditions by eHealthMe. Check the latest studies of Cavernous sinus thrombosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 24, 2026

24,091 people reported to have side effects when taking Enoxaparin sodium.
Among them, 12 people (0.05%) have Cavernous sinus thrombosis.

Could Enoxaparin sodium cause Cavernous sinus thrombosis?

Among these 12 people:

How long have people been on Enoxaparin sodium when they have Cavernous sinus thrombosis? *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Cavernous sinus thrombosis when taking Enoxaparin sodium? *

  • female: 55.56 %
  • male: 44.44 %

What is the age of people who have Cavernous sinus thrombosis when taking Enoxaparin sodium? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 11.11 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 88.89 %

What are other drugs people take besides Enoxaparin sodium? *

  1. Furosemide: 6 people, 50.00%
  2. Sitagliptin: 5 people, 41.67%
  3. Omeprazole: 5 people, 41.67%
  4. Gabapentin: 4 people, 33.33%
  5. Calcium Acetate: 4 people, 33.33%
  6. Mirtazapine: 4 people, 33.33%
  7. Aspirin: 4 people, 33.33%
  8. Tamsulosin: 4 people, 33.33%
  9. Sulfasalazine: 2 people, 16.67%
  10. Ramipril: 2 people, 16.67%

What are other side effects people have besides Cavernous sinus thrombosis? *

  1. Sinusitis (inflammation of sinus): 9 people, 75.00%
  2. Kidney Infection (Pyelonephritis): 5 people, 41.67%
  3. Intraventricular Haemorrhage (intraventricular bleeding): 5 people, 41.67%
  4. Conjunctival Oedema (conjunctival swelling): 5 people, 41.67%
  5. Ophthalmoplegia (a paralysis or weakness of one or more of the muscles that control eye movement): 5 people, 41.67%
  6. Pleocytosis (increased cell count): 5 people, 41.67%
  7. Depressed Level Of Consciousness: 5 people, 41.67%
  8. Drowsiness: 5 people, 41.67%
  9. Loss Of Consciousness: 5 people, 41.67%
  10. Eyes - Bulging (swelling of eyes): 5 people, 41.67%

What are the existing conditions these people have? *

  1. Headache (pain in head): 5 people, 41.67%
  2. Hypokalemia (low potassium): 2 people, 16.67%
  3. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 16.67%
  4. Bronchopulmonary Aspergillosis (lung disorder caused by aspergillus fungi): 2 people, 16.67%
  5. Enlarged Prostate: 2 people, 16.67%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 16.67%
  7. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 16.67%
  8. Acute Myocardial Infarction (acute heart attack): 2 people, 16.67%
  9. Insomnia (sleeplessness): 2 people, 16.67%
  10. Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Enoxaparin sodium and have Cavernous sinus thrombosis?

- Check whether Cavernous sinus thrombosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Enoxaparin sodium:

Cavernous sinus thrombosis treatments and more:

How severe was Cavernous sinus thrombosis and when was it recovered:

Expand to all the drugs that have ingredients of enoxaparin sodium:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Enoxaparin sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cavernous sinus thrombosis:

Browse all the conditions that are associated with Cavernous sinus thrombosis:


How the study uses the data?

The study uses data from the FDA. It is based on enoxaparin sodium (the active ingredients of Enoxaparin sodium) and Enoxaparin sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: